摘要
目的:探讨美沙拉嗪联合康复新液保留灌肠治疗溃疡性结肠炎(UC)的临床疗效及对患者血清炎症细胞因子、凝血指标的影响。方法:选取UC患者68例,按照随机数字表法将其分为病例组和对照组,各34例。对照组给予美沙拉嗪口服,病例组在对照组基础上联合康复新液保留灌肠,均连续治疗4周。比较两组治疗后的临床疗效,治疗前后的炎症细胞因子(TNF-α、IL-6、IL-8)及凝血指标(FIB、MPV)水平。结果:病例组总有效率为94.12%,高于对照组的73.53%,比较差异有统计学意义(P<0.05);治疗后,病例组TNF-α、IL-6、IL-8、FIB均低于对照组,但MPV水平高于对照组,比较差异均有统计学意义(P<0.05)。结论:美沙拉嗪联合康复新液保留灌肠治疗UC能协同减轻炎症反应、改善患者血液高凝状态,减轻肠黏膜损伤,提高临床疗效,临床上值得进一步研究。
Objective:To investigate the clinical efficacy of Mesalazine combined with Kangfuxin Solution retention enema in treatment of ulcerative colitis(UC) and its influence on serum inflammatory cytokines and coagulation index.Method:A total of 68 patients with UC were selected,according to the random number table method,they were divided into case group and control group,34 cases in each group.The control group was given Mesalazine orally,while the case group was given Kangfuxin Solution retention enema on the basis of control group,all of which were treated continuously for 4 weeks.The clinical efficacy,inflammatory cytokines(TNF-α,IL-6,IL-8) and coagulation indexes(FIB,MPV) before and after treatment between two groups were compared.Result:The total effective rate in case group was 94.12%,which was higher than 73.53% in control group,the difference was statistically significant(P<0.05).After treatment,the levels of TNF-α,IL-6,IL-8 and FIB in case group were lower than those of control group,but the MPV level was higher than that of control group,the differences were statistically significant(P<0.05).Conclusion:Mesalazine combined with Kangfuxin Solution retention enema in treatment of ulcerative colitis can synergistically reduce inflammatory reaction,improve blood hypercoagulability,reduce intestinal mucosal injury,improve clinical efficacy,which is worthy of further study.
作者
施彦卿
张娟
刘斌
张蒙蒙
谢敏华
蔡长春
胡敏
SHI Yanqing;ZHANG Juan;LIU Bin(Affiliated Hospital of Jiujiang University,Jiujiang 332000,China)
出处
《中国医学创新》
CAS
2018年第34期119-122,共4页
Medical Innovation of China
关键词
美沙拉嗪
康复新液
溃疡性结肠炎
炎症细胞因子
凝血指标
Mesalazine
Kangfuxin Solution
Ulcerative colitis
Inflammatory cytokine
Coagulation index
